NKGen Biotech (NKGN) Competitors $0.13 +0.00 (+1.19%) As of 04/17/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NKGN vs. JATT, OVID, MTEX, RNXT, CDIO, FNCH, PULM, CVM, ENLV, and NAIIShould you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include JATT Acquisition (JATT), Ovid Therapeutics (OVID), Mannatech (MTEX), RenovoRx (RNXT), Cardio Diagnostics (CDIO), Finch Therapeutics Group (FNCH), Pulmatrix (PULM), CEL-SCI (CVM), Enlivex Therapeutics (ENLV), and Natural Alternatives International (NAII). These companies are all part of the "pharmaceutical products" industry. NKGen Biotech vs. JATT Acquisition Ovid Therapeutics Mannatech RenovoRx Cardio Diagnostics Finch Therapeutics Group Pulmatrix CEL-SCI Enlivex Therapeutics Natural Alternatives International JATT Acquisition (NYSE:JATT) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, community ranking, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Does the media favor JATT or NKGN? In the previous week, NKGen Biotech had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for NKGen Biotech and 0 mentions for JATT Acquisition. JATT Acquisition's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score. Company Overall Sentiment JATT Acquisition Neutral NKGen Biotech Neutral Is JATT or NKGN more profitable? NKGen Biotech's return on equity of 0.00% beat JATT Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% NKGen Biotech N/A N/A -479.36% Do institutionals and insiders have more ownership in JATT or NKGN? 48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher valuation and earnings, JATT or NKGN? JATT Acquisition has higher earnings, but lower revenue than NKGen Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/ANKGen Biotech$80K71.64-$82.94M-$2.45-0.05 Does the MarketBeat Community favor JATT or NKGN? JATT Acquisition and NKGen Biotech both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformJATT AcquisitionN/AN/ANKGen BiotechN/AN/A SummaryNKGen Biotech beats JATT Acquisition on 4 of the 7 factors compared between the two stocks. Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKGN vs. The Competition Export to ExcelMetricNKGen BiotechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$5.73M$2.84B$5.30B$18.42BDividend YieldN/A1.86%5.12%4.20%P/E Ratio-0.0330.4821.7731.10Price / Sales71.64441.91379.4026.58Price / CashN/A168.6838.2617.54Price / Book-0.053.466.444.30Net Income-$82.94M-$72.06M$3.21B$1.02B7 Day Performance10.77%2.52%2.82%1.42%1 Month Performance-29.21%-15.73%-8.67%-7.33%1 Year Performance-85.17%-26.11%11.38%2.26% NKGen Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKGNNKGen BiotechN/A$0.13+1.2%N/A-87.6%$5.73M$80,000.00-0.03N/AJATTJATT AcquisitionN/A$1.21+8.0%N/A-62.2%$20.87MN/A0.003High Trading VolumeOVIDOvid Therapeutics4.1415 of 5 stars$0.29+2.5%$3.03+956.9%-90.7%$20.40M$566,000.00-0.6160Gap UpMTEXMannatech1.3179 of 5 stars$10.68+7.2%N/A+18.0%$20.30M$117.87M-13.19250Gap DownRNXTRenovoRx2.2159 of 5 stars$0.84+9.4%$6.00+610.2%-12.1%$20.28M$43,000.00-1.486Short Interest ↑Gap UpHigh Trading VolumeCDIOCardio Diagnostics1.8204 of 5 stars$0.39-4.1%$2.00+414.8%-61.8%$20.26M$34,890.000.001Short Interest ↑Negative NewsFNCHFinch Therapeutics GroupN/A$13.40+8.1%N/A+415.9%$19.91M$110,000.00-1.52190PULMPulmatrixN/A$5.39-0.2%N/A+202.3%$19.67M$7.81M-2.0420CVMCEL-SCIN/A$0.24-21.9%N/A-83.0%$19.16MN/A-0.5043Gap UpHigh Trading VolumeENLVEnlivex Therapeutics3.2874 of 5 stars$0.89-1.3%$10.00+1,028.4%-41.6%$18.97MN/A-0.9070Short Interest ↓Positive NewsGap UpNAIINatural Alternatives International1.2904 of 5 stars$3.04+3.1%N/A-58.6%$18.85M$121.85M-2.36290Short Interest ↓Gap UpHigh Trading Volume Related Companies and Tools Related Companies JATT Acquisition Alternatives Ovid Therapeutics Alternatives Mannatech Alternatives RenovoRx Alternatives Cardio Diagnostics Alternatives Finch Therapeutics Group Alternatives Pulmatrix Alternatives CEL-SCI Alternatives Enlivex Therapeutics Alternatives Natural Alternatives International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NKGN) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NKGN Stock Free NKGN Stock Alerts